Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Thyrocare Promoter Docon Technologies Offloads 10% Stake Worth Rs 667 Crore
The deal marks a major liquidity event for the promoter and signals renewed institutional interest in the diagnostics sector, which continues to evolve amid rising demand for preventive and digital healthcare solutions in India.
- By Newsdesk
- New Delhi
- Oct 27, 2025
In a significant market development, Docon Technologies Pvt Ltd, the promoter entity of Thyrocare Technologies Ltd, has sold about 10% of its stake in the diagnostics company for approximately ₹667.7 crore.
As per data from the National Stock Exchange (NSE), Docon offloaded nearly 53.32 lakh shares — representing 10.06% of Thyrocare’s paid-up equity — at an average price of ₹1,252.03 per share. The move reduces Docon’s holding in Thyrocare from roughly 71.06% to 60.93%.
The stake sale attracted strong participation from major institutional investors. Mutual funds such as ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, HDFC Mutual Fund, and Eastspring Investments collectively acquired around 42.11 lakh shares, accounting for approximately 7.95% of the company’s equity, for a total value of about ₹527.23 crore.
Following the transaction, Thyrocare’s shares closed 1.99% higher at ₹1,269.70 on the NSE, reflecting investor confidence in the company’s fundamentals.
The deal marks a major liquidity event for the promoter and signals renewed institutional interest in the diagnostics sector, which continues to evolve amid rising demand for preventive and digital healthcare solutions in India.
(Source: PTI)